AI Enhances Cancer Detection Across Over 40 Organs
Amsterdam, Friday, 7 February 2025.
Paige has upgraded its AI tool, PanCancer Detect, improving cancer detection in over 40 organs to enhance pathology workflows and identify rare cancer variants efficiently.
Groundbreaking Expansion of AI Cancer Detection
On February 5, 2025, Paige announced a significant enhancement to their PanCancer Detect tool, expanding its capabilities from the initial 17 tissue types launched in early 2024 to now cover more than 40 organ and tissue types [1][5]. The system is powered by Virchow V2, an advanced foundation model trained on 3 million digitized slides and incorporating 1.8 billion parameters [1][5], establishing a new benchmark in AI-driven cancer diagnostics.
Technical Innovation and Clinical Validation
The enhanced system demonstrates remarkable versatility in detecting not only common cancers but also rare variants and precancerous lesions [1]. As the first company to secure FDA clearance for an AI application in pathology [3], Paige has validated their technology through rigorous clinical testing. In an independent study examining 62 complex cases across 16 tissue types, the system proved its effectiveness by successfully identifying diagnostic discrepancies that were later confirmed by medical professionals [1].
Improved Efficiency in Pathology Workflows
The system’s impact on pathology workflows is significant, with demonstrated improvements in laboratory efficiency and diagnostic accuracy [2]. PanCancer Detect streamlines the diagnostic process by automatically screening cases and prioritizing those with cancer indicators, while also flagging potential diagnostic discrepancies [1]. The tool is currently available through Paige’s FullFocus image viewer and is expanding its accessibility through integration with leading digital pathology platforms including PathPresenter, Aiforia, Indica Labs, PathAI, and Gestalt [1][5].
Future Implications and Accessibility
Under the leadership of Siqi Liu, Director of AI Science at Paige, the company has transformed cancer detection into a broad, scalable AI solution [5]. The technology’s approach, which was initially demonstrated in Nature Medicine, represents a significant advancement in the field of digital pathology [1]. With its recent expansion, PanCancer Detect is positioned to address the growing need for efficient and accurate cancer diagnostics across a wider range of tissue types [1][5].